Cobra Biologics and BioCancell Collaborate on Cancer Therapy Drug - - BioPharm International

ADVERTISEMENT

Cobra Biologics and BioCancell Collaborate on Cancer Therapy Drug



Cobra Biologics, a contract manufacturer of clinical and commercial scale biologics and pharmaceuticals, and BioCancell have announced an agreement to manufacture BioCancell’s BC-821 cancer drug for clinical trials.

BioCancell’s Phase I clinical trial for BC-821, scheduled to launch in 2015, is a result of pre-clinical studies that examined the use of BC-821 as a treatment for several cancer indications such as non-small-celllung carcinoma, ovarian cancer, glioblastoma (brain tumour), and liver metastasis.

Cobra will provide GMP manufacture of BC-821 plasmid DNA, and fill and finish the product in accordance with aseptic manufacturing procedures before releasing it for clinical trials.

BC-821 is a potential therapeutic product that penetrates cancerous cells and activates the synthesis of DTA under the control of H19 and/or P4 promoter of the target gene IGF2. Both H19 and P4-IGF2 transcriptionfactors are expressed only in cancerous cells. An international patent application for this product was filed by BioCancell in 2008.

Source: Cobra Biologics

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

NIH Seeks to Improve Vaccine Response with New Adjuvants
September 30, 2014
New Report Details Players and Pipelines in the Biosimilar Space
September 30, 2014
Baxter International Plans to Open R&D Center for Baxalta
September 30, 2014
FDA Releases First-Ever Purple Book for Biosimilar Characterization
September 26, 2014
FDA and NIH Win Award for IP Licensing of Meningitis Vaccine
September 26, 2014
Author Guidelines

Click here